Predictors of chronic kidney disease among Indonesian adult population: Results from the 2018 Indonesia Basic Health Research

Rachmah, Qonita; Atmaka, Dominikus Raditya; Haryana, Nila Reswari; Daud, Zulfitri Azuan Mat

doi:10.12688/f1000research.130649.1

Cited by 1 publication

(1 citation statement)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chronic Kidney Disease (CKD) or renal failure is a condition characterized by a decline in kidney function due to damage, which can be evidenced by albuminuria, hematuria, structural and pathological abnormalities in the kidneys, or a glomerular filtration rate (GFR) of less than 60 mL/min/1.73 m² for at least three months (Kidney Health Australia, 2020). The prevalence of CKD in Indonesia increased from 0.2% in 2013 to 0.3% in 2018 (Hidayangsih et al, 2023;Rachmah et al, 2023). Additionally, a study found that the prevalence of CKD in Indonesia in 2018 was 0.38%, with varying rates across different provinces, such as 0.64% in North Kalimantan and 0.18% in West Sulawesi (Ro'di et al, 2023).…”

Section: Introductionmentioning

confidence: 99%

The Effect of Intravenous Oxyhydrogen Nanobubble on Chronic Kidney Disease: Case Series

Indrajani,

Hernowo,

Ekasari

et al. 2024

Preprint

View full text Add to dashboard Cite

Background. Chronic kidney disease (CKD) is a progressive condition with limited treatment options that often lead to significant morbidity. Recent studies suggest that oxyhydrogen nanobubbles (HHOnb) may offer therapeutic benefits due to their antioxidative and anti-inflammatory properties. This case series examines the effects of intravenous HHOnb therapy on three patients with varying stages of CKD.Methods. Three patients with CKD underwent a series of ten HHOnb infusions over a period of two to three months. The patients, aged 43 to 70, presented with additional comorbidities including hypertension, diabetes mellitus, and polycystic kidney disease. Clinical parameters, including glomerular filtration rate (GFR), serum creatinine, blood pressure, and uric acid levels, were monitored alongside subjective health improvements.Results. Patient A. A 70-year-old woman with CKD grade 3a experienced a reduction in serum creatinine from 0.98 mg/dL to 0.82 mg/dL and an improvement in GFR from 59 mL/min/1.73 m² to 73.2 mL/min/1.73 m². She reported reduced leg swelling and increased vitality. Patient B. A 52-year-old man with CKD grade 4 and class III obesity showed a decrease in serum creatinine from 3.0 mg/dL to 2.86 mg/dL, an increase in GFR from 23 mL/min/1.73 m² to 24.4 mL/min/1.73 m², and improved sleep quality. Blood pressure reduced from 167/82 mmHg to 145/85 mmHg. Patient C. A 43-year-old man with CKD grade 4 and massive polycystic kidney disease reported reduced fatigue and normalized urination. His serum creatinine decreased from 3.26 mg/dL to 3.09 mg/dL, and his GFR improved from 22 mL/min/1.73 m² to 23.6 mL/min/1.73 m².Conclusion. Intravenous HHOnb therapy demonstrated potential benefits in improving renal function and overall health in CKD patients. These findings suggest that HHOnb could be a promising complementary treatment for CKD, though larger, controlled studies are needed to confirm its efficacy and safety.

show abstract

Section: Introductionmentioning

confidence: 99%